Cardiogen
Also known as: Peptídeo miocárdico
Molecular Identifiers
Overview
Myocardial bioregulatory tetrapeptide developed by the Khavinson group. Regulates gene expression in cardiac tissue and supports cardiomyocyte function. Used in short cycles for cardiovascular protection and support.
The interest in Cardiogen lies in its trophic support to the myocardium: regulation of gene expression in cardiomyocytes, normalization of cardiac energy metabolism, and modulation of the oxidative stress response. It is proposed as an adjunct in cardiovascular bioregulation protocols, especially in aging or functional recovery contexts, without replacing conventional therapy.
It has no approval as a medicine by the FDA, EMA, or ANVISA. It circulates mainly through compounding pharmacies and specialized suppliers of Russian-school peptides, in short cycles of 10-20 days repeated 2-4 times per year, often combined with Vesugen.
It was developed within the line of short bioregulatory peptides led by Vladimir Khavinson's group in St. Petersburg, which applied the same logic of tissue-specific fragments to several organs. Most of the evidence comes from Russian-language literature and preclinical studies; robust international clinical trials are still scarce.
Within the Khavinson family, Cardiogen occupies the cardiac niche and is often discussed alongside Vesugen, a short peptide aimed at the vascular endothelium: Cardiogen is presented with a focus on the cardiomyocyte and myocardial energy metabolism, while Vesugen is described as acting on the vessel wall. All of this comparative literature is largely Russian and preclinical.
AEDR Ala-Glu-Asp-Arg Half-life
~2-4 hours
Administration Route
Subcutaneous or intramuscular
Category
Specialized Research
Mechanism of Action
- Regulation of gene expression in myocardial tissue
- Support for cardiomyocyte function and viability
- Normalization of cardiac energy metabolism
- Modulation of oxidative stress response in the myocardium
- Bioregulatory effect on the cardiovascular system
Reported Side Effects
Adverse effects described in the literature. Severity and frequency vary between individuals.
- Injection site pain
- Local redness (rare)
Product Properties
| Purity | >95% |
| Appearance | White lyophilized powder |
| Solubility | Freely soluble in water and bacteriostatic water |
| Source | Solid-phase peptide synthesis (SPPS) |
| Storage | Lyophilized: -20°C for up to 2 years, 2-8°C for up to 6 months. Reconstituted: 2-8°C for up to 4 weeks. Protect from light and moisture. Very stable short peptide — tolerates brief temperature excursions. |
Presentations & Preparation
Vials of Cardiogen found in the research market:
Reconstitution
- Diluent: Bacteriostatic water
- Volume: 2 ml per vial
- Slowly inject the diluent against the vial wall
- Gently swirl until fully dissolved
- Never shake
Storage
- Lyophilized: Refrigerated 2-8°C
- Reconstituted: Refrigerated 2-8°C (up to 30 days)
- Protect from direct light
- Do not freeze after reconstitution
Scientific Studies
Published studies on Cardiogen.
Related Peptides
Aviptadil
50-150 mcg per administration (IV or subcutaneous) · 1-3 times daily per protocol
B7-33
Bronchogen
1-2 capsules orally (0.2 g per capsule, containing AKS-B peptide complex) · 1-2 times daily, with meals
Chonluten
1-2 capsules orally (0.2 g per capsule, containing bronchial tissue peptide complex) · 1-2 times daily, with meals
Crystagen
1-2 capsules orally (0.2 g per capsule, containing AKS-6 peptide complex) · 1-2 times daily, before meals
Dalargin
1-2 mg per injection (subcutaneous or intramuscular) · 1-2 times daily